Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock. A Randomised, Double-blind, Two-Stage, Placebo Controlled Study
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Nangibotide (Primary)
- Indications Septic shock
- Focus Adverse reactions
- Sponsors Inotrem
- 04 Jul 2017 Status changed from not yet recruiting to recruiting.
- 09 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jun 2017.
- 22 May 2017 New trial record